Innovator Emerging Markets Power Buffer ETF July (ARCA: EJUL)

Latest news for Innovator Emerging Markets Power Buffer ETF July (ARCA:EJUL)

The fund will normally invest at least 80% of its net assets (including investment borrowings) in securities that comprise the index. The IBD 50 Index is a weekly, rules-based, computer-generated stock index compiled and published by Investors Business Daily (IBD or the index provider) that seeks to identify the current top 50 growth stocks.

Innovator Emerging Markets Power Buffer ETF - July

Innovator Emerging Markets Power Buffer ETF July

News

Guidance

Management

Tech

ASML

ASML CEO Said AI-driven Shift Toward Advanced Logic And Memory Chips Benefits ASML

Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 33.33 percent increase over losses of $(0.36) per share from the same period last year.

Earnings

Earnings Beats

RANI

Rani Therapeutics Hldgs Q3 EPS $(0.24) Beats $(0.27) Estimate

IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(1.41) by 70.92 percent.

IMCC

IM Cannabis Q3 2024 Adj EPS $(0.41) Beats $(1.41) Estimate

UBS analyst Michael Goldsmith downgrades Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) from Buy to Neutral and lowers the price target from $155 to $134.

Downgrades

Price Target

Analyst Ratings

UBS Downgrades Sun Communities to Neutral, Lowers Price Target to $134

&nbsp;Enlivex Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period for the first patient in its Phase I clinical trial evaluating the safety, tolerability and potential therapeutic effect of Allocetra&#x2122; following injection into an affected joint in patients with psoriatic arthritis. No safety concerns were recorded following the dosing of the first patient.
The trial currently plans to recruit six patients who have insufficiently responded to conventional therapies for psoriatic arthritis. The primary safety endpoint will measure the frequency and severity of adverse events and serious adverse events, and secondary endpoints will include assessments of change from baseline in pain and other parameters of disease activity for up to 12 months following administration of Allocetra&#x2122;.

Biotech

General

ENLV

Enlivex Announces The Dosing Of The First Patient In A Phase I Clinical Trial  Evaluating The Safety, Tolerability And Potential Therapeutic Effect Of Allocetra In Patients With Psoriatic Arthritis

ASML CEO, AT Investor Day, Says Sees Global Chip Market Growing 9% Annually And Passing $1T In 2030; Sees AI Chips Making Up 40% Of Total Market In 2030 After Rapid Growth

Expands Arabic Content With New Series And Exclusive Concerts, Partners With UAE Telcos For 4K Streaming And Saudi Ministry Of Culture For Talent Development

AAPL

ANGH

Anghami Reports Strong 2024 Growth With 28% Increase In Video Streaming Engagement And 18% ARPU Rise; Launches AI-Driven Features, DolbyVision, And Apple Vision Pro App

Oppenheimer analyst Christopher Glynn maintains Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) with a Outperform and raises the price target from $260 to $305.

Oppenheimer Maintains Outperform on Applied Industrial Techs, Raises Price Target to $305

JD.com,&nbsp;Inc.&nbsp;(NASDAQ:&nbsp;JD) reported fiscal second-quarter 2024 revenue growth of 5.1%&nbsp;year over year&nbsp;to $37.11 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41964595/jd-com-announces-third-quarter-2024-results" rel="noreferrer noopener">analyst consensus estimate of $36.54 billion</a>.
JD posted&nbsp;an adjusted net income per ADS of $1.24, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $1.09</a>. The stock price slid after the print.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41943966/stratasys-ceo-touts-turnaround-strong-market-gains-cost-cuts-drive-q3-beat-guidance-raised" rel="noreferrer noopener">Stratasys CEO Touts Turnaround: Strong Market Gains, Cost Cuts Drive Q3 Beat, Guidance Raised</a>
JD Segment Performance: JD.com's&nbsp;net product revenue increased by 4.8%&nbsp;year over year&nbsp;at $29.16 billion. Net service revenues rose 6.5%&nbsp;year over year&nbsp;to $7.95 billion.&nbsp;
JD Retail revenue climbed 6.1%&nbsp;year over year&nbsp;to $32.06 billion, Logistics revenue gained 6.6% year over year to $6.33 billion, and the new business revenues fell to $708 million.
JD.com's marketing expenses rose 25.7% to $1.4 billion in the quarter, forming 3.8% of revenues. The rise was mainly due to the increased spending in promotion activities.
Margin: Operating margin was 4.6% for the quarter, compared to 3.8% year over year. Adjusted operating margin improved 50 bps year over year to 5.0%. JD Retail's operating margin remained stable year over year at 5.2%.&nbsp;
Adjusted EBITDA increased 17.0% year over year to $2.1 billion, with a 5.8% margin.
JD.com used $1.97 billion in free cash flow for the quarter, used $0.89 billion in operating cash flow, and held $28.0 billion in cash and equivalents as of September-end.
JD.com's CEO, Sandy Xu, highlighted strong topline growth and solid profitability in the third quarter, driven by improved consumer sentiment. Xu attributed the performance to JD.com's robust supply chain and fulfillment infrastructure, which played a key role in China's trade-in program. The company saw significant growth in the general merchandise category, fueled by efforts to enhance user experience and positive responses to the Singles Day Grand Promotion.
CFO Ian Su Shan noted that JD.com's revenues grew 5.1% year-over-year, supported by a rebound in electronics and home appliance sales alongside consistent strength in general merchandise. The company's focus on enhancing supply chain capabilities led to improved gross and non-GAAP net margins.
JD.Com stock gained over 31% year-to-date.
Price Action: JD stock is up 1.65% at $36.28 in the premarket session&nbsp;at the last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41940062/tower-semiconductor-q3-earnings-revenue-and-profit-beat-plans-350-million-expansion" target="_blank" rel="noreferrer noopener">Tower Semiconductor Q3 Earnings: Revenue And Profit Beat, Plans $350 Million Expansion</a></li>
</ul>
Photo via Wikimedia Commons

Emerging Markets

JD.com Q3 Earnings: Revenue Beats Forecast Amid Consumer Rebound, Highlights Supply Chain Strength, Eyes Margin Growth

Oppenheimer analyst Hartaj Singh maintains Astria Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) with a Outperform and raises the price target from $26 to $28.

ATXS

Oppenheimer Maintains Outperform on Astria Therapeutics, Raises Price Target to $28

<a href="https://www.msn.com/en-us/money/markets/crude-oil-production-we-ve-reached-1-8m-barrels-per-day-nnpcl/ar-AA1u4xVK?ocid=finance-verthp-feeds" title="https://www.msn.com/en-us/money/markets/crude-oil-production-we-ve-reached-1-8m-barrels-per-day-nnpcl/ar-AA1u4xVK?ocid=finance-verthp-feeds">https://www.msn.com/en-us/money/markets/crude-oil-production-we-ve-reached-1-8m-barrels-per-day-nnpcl/ar-AA1u4xVK?ocid=finance-verthp-feeds</a>

Macro Economic Events

Commodities

Economics

Markets

Nigerian National Petroleum Company Limited Reaches 1.8M Barrels Per Day Of Oil Production

Sow Good (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOWG#NASDAQ">SOWG</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. This is a 925 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $3.55 million which missed the analyst consensus estimate of $5.47 million by 35.02 percent. This is a 29.40 percent decrease over sales of $5.03 million the same period last year.

Earnings Misses

SOWG

Sow Good Q3 EPS $(0.33) Misses $(0.18) Estimate, Sales $3.55M Miss $5.47M Estimate

Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) with a Outperform and raises the price target from $63 to $65.

TARS

Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $65

UBS analyst Christopher Schoell initiates coverage on Cogent Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NASDAQ">CCOI</a>) with a Buy rating and announces Price Target of $102.

Initiation

CCOI

UBS Initiates Coverage On Cogent Comms Hldgs with Buy Rating, Announces Price Target of $102

Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) today announced that data from four studies of sotagliflozin will be delivered during the American Heart Association's (AHA) Sessions 2024 being held November 16-18 at McCormick Place Convention Center in Chicago, Illinois.
One of those studies, a secondary analysis of data from the Phase 3 SCORED clinical trial, examined the association of heart failure stage with cardiovascular disease and kidney events. Researchers in the study observed that sotagliflozin had similar relative benefits for all endpoints, irrespective of heart failure stage, with a corresponding increase in absolute benefits at earlier stages.

LXRX

Lexicon Pharmaceuticals Reports Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum Of Heart Failure Patient Populations Is Among Four Presentations At The American Heart Association's Sessions 2024 in Chicago

WIIM

ONEW

OneWater Marine shares are trading lower after the company reported worse-than-expected Q4 financial results.

HC Wainwright &amp; Co. analyst Scott Buck maintains SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) with a Buy and raises the price target from $7 to $8.

SOUN

HC Wainwright & Co. Maintains Buy on SoundHound AI, Raises Price Target to $8

CINT

CI&T shares are trading higher. The company reported Q3 financial results.

Tokyo Lifestyle Co., Ltd. ("Tokyo Lifestyle" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, as well as other products in&nbsp;Hong Kong,&nbsp;Japan,&nbsp;North America and the&nbsp;United Kingdom, today announced the launch of a new online sales platform for its Reiwatakiya brand in Canada. The platform, available at <a href="https://www.globenewswire.com/Tracker?data=enpJZN8oFHmWH6LdX3v8bxJbYYdvwBcbSfWm8eJ9hom9gTkrIJAGlIR_PqHjUUESagXds0de2HA0i7t0NgOjW1lHNkSmBqHeO7fLXE4xQY3SozpzHyI8XG3v0x5tarXQ">https://reiwatakiyatoronto.com</a>, will serve as a one-stop online hub for North American customers, offering authentic Japanese health, beauty, and lifestyle products with local shipping options across North America. This launch represents a major milestone in the Company's regional expansion strategy.

TKLF

Tokyo Lifestyle Co. Launches New Online Platform For Reiwatakiya Brand in Canada, Expanding North American Presence

<a href="https://www.aboutamazon.com/news/retail/amazon-one-medical-pharmacy-prescriptions-common-conditions" title="https://www.aboutamazon.com/news/retail/amazon-one-medical-pharmacy-prescriptions-common-conditions">https://www.aboutamazon.com/news/retail/amazon-one-medical-pharmacy-prescriptions-common-conditions</a>

AMZN

Amazon Launches Affordable Telehealth Service For Prime Members With Low Upfront Pricing For Men's Hair Loss, Anti-Aging, ED, And More; Offers Pay-Per-Visit Telehealth For 30+ Conditions And Expands Amazon Pharmacy's Fast, Free Medication Delivery

Comments

Innovator Emerging Markets Power Buffer ETF July

News

Latest news for Innovator Emerging Markets Power Buffer ETF July (ARCA:EJUL)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga